Investor Overview

Corporate Profile

AtriCure is a medical device company providing innovative solutions designed to decrease the global Afib epidemic.

Stock Quote

(Common)
Price	Change	% Change	Volume

Previous Close	Today's Open	Intraday High	Intraday Low

Exchange: (US Dollar)
Mar 31, 2020 9:10 PM EDT

Date	Title
02/25/20	Investor Presentation 3.1 MB
02/18/20	Q4 and Full Year 2019 Earnings Call Transcript 140.3 KB
08/12/19	Acquisition of SentreHEART Overview 778.9 KB
04/10/19	2018 Annual Report 4.4 MB

Date	Title
02/18/20	AtriCure Reports Fourth Quarter 2019 and Full Year 2019 Financial Results 2019 Worldwide revenue of $230.8 million – an increase of 14.5% year over year 2019 U.S. revenue of $185.8 million – an increase of 14.6% year over year 2019 International revenue of $45.0 million – an increase of 13.9% year over year MASON, Ohio --(BUSINESS WIRE)--Feb. 18, 2020-- AtriCure, Inc .
02/03/20	AtriCure to Participate at the SVB Leerink 9th Annual Global Healthcare Conference MASON, Ohio --(BUSINESS WIRE)--Feb. 3, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming SVB Leerink 9 th Annual Global
01/28/20	AtriCure to Announce Fourth Quarter and Full Year 2019 Financial Results MASON, Ohio --(BUSINESS WIRE)--Jan. 28, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2019 financial results on Tuesday,
01/13/20	AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2019, Provides Financial Outlook for 2020 MASON, Ohio --(BUSINESS WIRE)--Jan. 13, 2020-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quarter and full year 2019 and provided 2020 financial

Date	Title
02/18/20	AtriCure Reports Fourth Quarter 2019 and Full Year 2019 Financial Results 2019 Worldwide revenue of $230.8 million – an increase of 14.5% year over year 2019 U.S. revenue of $185.8 million – an increase of 14.6% year over year 2019 International revenue of $45.0 million – an increase of 13.9% year over year MASON, Ohio --(BUSINESS WIRE)--Feb. 18, 2020-- AtriCure, Inc .
02/03/20	AtriCure to Participate at the SVB Leerink 9th Annual Global Healthcare Conference MASON, Ohio --(BUSINESS WIRE)--Feb. 3, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming SVB Leerink 9 th Annual Global
01/13/20	AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2019, Provides Financial Outlook for 2020 MASON, Ohio --(BUSINESS WIRE)--Jan. 13, 2020-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quarter and full year 2019 and provided 2020 financial
01/07/20	AtriCure Announces Successful Completion of Patient Enrollment of aMAZE Clinical Trial and FDA Approval of Continued Access Protocol MASON, Ohio --(BUSINESS WIRE)--Jan. 7, 2020-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the successful completion of patient enrollment in the aMAZE™ clinical trial.

More National News >>

Date	Title
08/13/19	AtriCure Completes Acquisition of SentreHEART MASON, Ohio --(BUSINESS WIRE)--Aug. 13, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has completed its previously announced acquisition of SentreHEART, Inc.
08/28/18	AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial Landmark study is the first prospective, randomized study comparing the Convergent approach to endocardial catheter ablation in persistent and long-standing persistent atrial fibrillation patients MASON, Ohio --(BUSINESS WIRE)--Aug. 28, 2018-- AtriCure, Inc.
06/05/18	AtriCure and Baheal Group Establish Partnership and China Distribution Agreement Baheal will serve as the exclusive distribution partner for AtriCure products across China MASON, Ohio--(BUSINESS WIRE)--Jun. 5, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes...
04/25/17	AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide AtriClip is the most widely used device globally for left atrial appendage management MASON, Ohio --(BUSINESS WIRE)--Apr. 25, 2017-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it

More International News >>